Cantor Fitzgerald raises Abbvie stock price target to $250 on strong Skyrizi performance

Investing.comThursday, October 9, 2025 at 11:45:10 AM
Cantor Fitzgerald raises Abbvie stock price target to $250 on strong Skyrizi performance
Cantor Fitzgerald has raised its price target for Abbvie's stock to $250, citing strong performance from the drug Skyrizi. This is significant as it reflects confidence in Abbvie's growth potential and the effectiveness of Skyrizi in treating conditions like psoriasis. Investors may see this as a positive indicator for Abbvie's future, potentially leading to increased interest in the stock.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Lutnick Sons See Record Year as Cantor Denies Trump Conflicts
PositiveFinancial Markets
Cantor Fitzgerald, a New York financial boutique, is controlled by Brandon and Kyle Lutnick, sons of Howard Lutnick, who recently joined President Donald Trump's administration as Commerce Secretary. The firm is projected to achieve record revenue of over $2.5 billion in 2025, largely driven by a surge in crypto dealmaking and expansion into sectors such as rare-earth minerals, quantum computing, robotics, and data centers. Despite their success, many executives at Cantor Fitzgerald reject the notion that their connections in Washington are a factor in their achievements. Bloomberg's Todd Gillespie discussed these developments on 'Bloomberg Businessweek Daily'.
AbbVie at 7th Annual Healthcare Symposium: Navigating Vaccine Hesitancy
NeutralFinancial Markets
AbbVie participated in the 7th Annual Healthcare Symposium, focusing on the critical issue of vaccine hesitancy. The event highlighted the importance of addressing public concerns and misinformation surrounding vaccines to improve vaccination rates and public health outcomes.